The area of residual tumor predicts esophageal squamous cell carcinoma prognosis following neoadjuvant chemotherapy.
Esophageal neoplasm
Neoadjuvant therapy
Pathology
Residual tumor
Response evaluation criteria in solid tumors
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
04
08
2022
accepted:
16
09
2022
medline:
19
7
2023
pubmed:
7
10
2022
entrez:
6
10
2022
Statut:
ppublish
Résumé
To clarify the utility of the area of residual tumor for patients with esophageal squamous cell cancer treated with neoadjuvant chemotherapy. We enrolled 186 patients with esophageal squamous cell cancer who underwent surgical resection following neoadjuvant chemotherapy at our hospital. Using digital images, we measured the area of residual tumor at the maximum plane of the specimen and divided the patient into three groups as follows: 0 (area = 0 mm2), low (area = 0-40 mm2), and high (area ≥ 40 mm2). The clinicopathological factors and prognosis were compared among these groups. The median area of the residual tumor was 15.0 mm2 (range 0-1,448.8 mm2). Compared with the 0 and low group, the high group was significantly associated with poorer recurrence-free survival (all P < .001) and overall survival (P < .001 [vs. 0] and P = .017 [vs low]). The area of residual tumor, ypN, tumor regression grade, and lymphovascular invasion were independent predictors of recurrence-free survival. By dividing the patients using a combination of the area of residual tumor and lymphovascular invasion, the high and/or lymphovascular invasion ( +) group displayed significantly poor recurrence-free survival than the 0 group and low/lymphovascular invasion ( -) group. However, there was no significant difference in the recurrence-free survival between the 0 group and low/lymphovascular invasion ( -) group. The area of residual tumor is a promising histopathological prognostic factor for patients with esophageal squamous cell cancer treated with neoadjuvant chemotherapy. Moreover, it is a possible candidate histopathological factor for postoperative chemotherapy selection.
Identifiants
pubmed: 36201027
doi: 10.1007/s00432-022-04366-7
pii: 10.1007/s00432-022-04366-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4663-4673Subventions
Organisme : Japan Society for the Promotion of Science
ID : KAKENHI JP20K22859 and JP21K06899
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bankhead P (2022) Developing image analysis methods for digital pathology. J Pathol 257:391–402. https://doi.org/10.1002/path.5921
doi: 10.1002/path.5921
pubmed: 35481680
pmcid: 9324951
Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton AR, Wu T (2005) Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103:1347–1355. https://doi.org/10.1002/cncr.20916
doi: 10.1002/cncr.20916
pubmed: 15719440
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, Hajbi FE, Bartolomeo MD, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y (2022) Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386:449–462. https://doi.org/10.1056/NEJMoa2111380
doi: 10.1056/NEJMoa2111380
pubmed: 35108470
Donohoe CL, O’Farrell NJ, Grant T, King S, Clarke L, Muldoon C, Reynolds JV (2013) Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann Surg 258:784–792. https://doi.org/10.1097/SLA.0b013e3182a66588
doi: 10.1097/SLA.0b013e3182a66588
pubmed: 24045450
Eguchi Y, Nakai T, Kojima M, Wakabayashi M, Sakamoto N, Sakashita S, Miyazaki S, Taki T, Watanabe R, Watanuki R, Yamauchi C, Iwatani T, Mukohara T, Onishi T, Ishii G (2022) Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy. Cancer Sci 113:1507–1518. https://doi.org/10.1111/cas.15273
doi: 10.1111/cas.15273
pubmed: 35143092
pmcid: 8990870
Hatogai K, Fujii S, Kojima T, Daiko H, Kadota T, Fujita T, Yoshino T, Doi T, Takiguchi Y, Ohtsu A (2016) Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. J Surg Oncol 113:390–396. https://doi.org/10.1002/jso.24151
doi: 10.1002/jso.24151
pubmed: 27100024
Japan Esophageal Society (2017) Japanese classification of esophageal cancer, 11th edition: part I. Esophagus 14:1–36. https://doi.org/10.1007/s10388-016-0551-7
doi: 10.1007/s10388-016-0551-7
Kameyama A, Ye J, Shimomura A, Yokohira M, Nakano-Narusawa Y, Yamakawa K, Mukai Y, Sanomura T, Okuyama H, Miyatake N, Furihata M, Tanaka C, Kitazawa R, Bando Y, Suemitsu Y, Kojima M, Mino-Kenudson M, Suzuki Y, Okano K, Matsuda Y (2021) Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. Pancreatology 21:1506–1515. https://doi.org/10.1016/j.pan.2021.09.006
doi: 10.1016/j.pan.2021.09.006
pubmed: 34563448
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244
doi: 10.1038/bmt.2012.244
pubmed: 23208313
Kato K, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, Kojima T, Abe T, Bamba T, Watanabe M, Kawakubo H, Shibuya Y, Tsubosa Y, Takegawa N, Kajiwara T, Baba H, Ueno M, Machida R, Nakamura K, Kitagawa Y (2022) A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol 40:238–238. https://doi.org/10.1200/JCO.2022.40.4_suppl.238
doi: 10.1200/JCO.2022.40.4_suppl.238
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van EC, Piessen G, Mendez G, Feliciano J, Motoyama S, Lievre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M (2021) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384:1191–1203. https://doi.org/10.1056/NEJMoa2032125
doi: 10.1056/NEJMoa2032125
pubmed: 33789008
Kojima M, Ishii G, Yamane Y, Nishizawa Y, Saito N, Ochiai A (2009) Area of residual tumor beyond the muscular layer is a useful predictor of outcome in rectal cancer patients who receive preoperative chemoradiotherapy. Pathol Int 59:857–862. https://doi.org/10.1111/j.1440-1827.2009.02464.x
doi: 10.1111/j.1440-1827.2009.02464.x
pubmed: 20021610
Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier J, Bonvalot S, Gignoux M (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations Cancer 73:2680–2686. https://doi.org/10.1002/1097-0142(19940601)73:11%3c2680::aid-cncr2820731105%3e3.0.co;2-c
doi: 10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c
pubmed: 8194005
Martinez CG, Öztürk SZ, Al-Kaabi A, Valkema MJ, Bokhorst JM, Rosman C, Rutten H, Wauters CAP, Doukas M, van Lanschot JJ, Siersema PD, Nagtegaal ID, van der Post RS (2022) Shrinkage versus fragmentation response in neoadjuvantly treated oesophageal adenocarcinoma: significant prognostic relevance. Histopathology 80:982–994. https://doi.org/10.1111/his.14644
doi: 10.1111/his.14644
Matsuda Y, Ohkubo S, Nakano-Narusawa Y, Fukumura Y, Hirabayashi K, Yamaguchi H, Sahara Y, Kawanishi A, Takahashi S, Arai T, Kojima M, Mino-Kenudson M (2020) Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Sci Rep 10:18278. https://doi.org/10.1038/s41598-020-74067-z
doi: 10.1038/s41598-020-74067-z
pubmed: 33106543
pmcid: 7588464
Murphy MB, Xiao L, Patel VR, Maru DM, Correa AM, Amlashi FG, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA (2017) Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer 123:4106–4113. https://doi.org/10.1002/cncr.30953
doi: 10.1002/cncr.30953
Nakao R, Konishi E, Fujiwara H, Otsuji E, Yokota I, Urata Y, Yanagisawa A (2019) Residual cancer volume predicts clinical outcome in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy. Int J Surg Pathol 27:713–721. https://doi.org/10.1177/1066896919855760
doi: 10.1177/1066896919855760
pubmed: 31203677
Oguma J, Ishiyama K, Kurita D, Kanematsu K, Fujii Y, Kubo K, Yamamoto S, Honma Y, Kato K, Daiko H (2022) Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery. Esophagus 19:214–223. https://doi.org/10.1007/s10388-021-00891-5
doi: 10.1007/s10388-021-00891-5
pubmed: 34757482
Okubo S, Kojima M, Matsuda Y, Hiroki M, Shimizu Y, Toyama H, Morinaga S, Gotohda N, Uesaka K, Ishii G, Mino-Kenudson M, Takahashi S (2019) Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Sci Rep 9:17145. https://doi.org/10.1038/s41598-019-53801-2
doi: 10.1038/s41598-019-53801-2
pubmed: 31748528
pmcid: 6868132
Rice TW, Ishwaran H, Kelsen DP, Hofstetter WL, Apperson-Hansen C, Blackstone EH. (2016) Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 29:906–912
Rice TW, Kelsen D, Blackstone EH, Ishwaran H, Patil DT, Bass AJ, Erasmus JJ, Gerdes H, Hofstetter WL (2017) Esophagus and Esophagastoric Junction. In: Amin MB (ed) AJCC cancer staging manual, 8th edn. Springer, New York, pp 185–202
doi: 10.1007/978-3-319-40618-3_16
Sakuyama N, Kojima M, Kawano S, Matsuda Y, Mino-Kenudson M, Ochiai A, Ito M (2018) Area of residual tumor is a robust prognostic marker for patients with rectal cancer undergoing preoperative therapy. Cancer Sci 109:871–878. https://doi.org/10.1111/cas.13521
doi: 10.1111/cas.13521
pubmed: 29388280
pmcid: 5834774
Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP, Hoelscher AH (2005) Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 242:684–692. https://doi.org/10.1097/01.sla.0000186170.38348.7b
doi: 10.1097/01.sla.0000186170.38348.7b
pubmed: 16244542
pmcid: 1409844
Shah MA, Hofstetter WL, Kennedy EB (2021) Immunotherapy in patients with locally advanced esophageal carcinoma: ASCO treatment of locally advanced esophageal carcinoma guideline rapid recommendation update. J Clin Oncol 39:3182–3184. https://doi.org/10.1200/JCO.21.01831
doi: 10.1200/JCO.21.01831
pubmed: 34406872
Shah MA, Kennedy EB, Catenacci DV, Deighton DC, Goodman KA, Malhotra NK, Willett C, Stiles B, Sharma P, Tang L, Wijnhoven BPL, Hofstetter WL (2020) Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol 38:2677–2694. https://doi.org/10.1200/JCO.20.00866
doi: 10.1200/JCO.20.00866
pubmed: 32568633
Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H, Ochiai A (2010) A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor. J Thorac Oncol 5:49–55. https://doi.org/10.1097/JTO.0b013e3181c0a1f8
doi: 10.1097/JTO.0b013e3181c0a1f8
pubmed: 20035185
Yun JK, Kim Y, Lee GD, Choi S, Kim YH, Kim DK, Park SI, Kim HR (2022) Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. Cancer Med. https://doi.org/10.1002/cam4.4748(PublishedonlineApril17,2022)
doi: 10.1002/cam4.4748(PublishedonlineApril17,2022)
pubmed: 35733293
pmcid: 9761085